GLP-1 Drugs Resolve Fatty Liver Disease and Improve Scarring in Meta-Analysis of Clinical Trials

This was a meta-analysis of six randomized controlled trials identified through a literature search up to May 2025. All trials evaluated FDA-approved GLP-1 receptor agonists in patients with biopsy-confirmed MASH. The primary outcomes were MASH resolution without fibrosis worsening and fibrosis improvement without MASH worsening at 12-18 months. The analysis included 1,555 patients total — 1,082 on GLP-1RAs and 473 on placebo. Subgroup analysis was performed excluding studies that included cirrhotic patients.

MASH is the most common chronic liver disease worldwide and a leading cause of liver transplantation, yet treatment options have been extremely limited until recently. The first drug specifically approved for MASH (resmetirom) only arrived in 2024. This meta-analysis provides the strongest evidence to date that GLP-1 receptor agonists — already widely prescribed for diabetes and obesity — can resolve the underlying liver disease and even reverse early scarring. This could fundamentally change how clinicians manage the large overlap population of patients with diabetes, obesity, and fatty liver disease.

This meta-analysis arrives at a pivotal moment for liver disease treatment. MASH has long been an area of unmet medical need with multiple clinical trial failures. GLP-1 receptor agonists — particularly semaglutide — have emerged as leading candidates alongside thyroid hormone receptor agonists. The dual benefit of resolving liver inflammation while also addressing the underlying metabolic drivers (obesity, insulin resistance) positions GLP-1RAs uniquely among MASH treatments. The fibrosis regression finding is particularly significant, as liver fibrosis is the strongest predictor of liver-related mortality.

The meta-analysis included only six trials with 1,555 patients, which is moderate but not large for a meta-analysis. Individual GLP-1RA drugs were pooled together, which may mask differences in efficacy between specific medications. The fibrosis benefit was significant only in the subgroup excluding cirrhotic patients, suggesting GLP-1RAs may not help those with advanced disease. Follow-up was limited to 12-18 months — the long-term effects on liver outcomes like decompensation, hepatocellular carcinoma, and transplant need remain unknown.